News articles about Alder BioPharmaceuticals (NASDAQ:ALDR) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alder BioPharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.091018025283 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern Sentiment’s rankings:

Alder BioPharmaceuticals (ALDR) traded up 3.83% on Friday, hitting $10.85. The company’s stock had a trading volume of 936,434 shares. The firm’s market cap is $734.69 million. Alder BioPharmaceuticals has a 12 month low of $8.60 and a 12 month high of $35.62. The firm has a 50 day moving average of $9.64 and a 200 day moving average of $15.75.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, topping analysts’ consensus estimates of ($1.67) by $0.19. The business had revenue of $0.68 million during the quarter. The firm’s quarterly revenue was up 518.2% compared to the same quarter last year. During the same period last year, the business earned ($0.79) earnings per share. Equities research analysts forecast that Alder BioPharmaceuticals will post ($5.71) earnings per share for the current fiscal year.

A number of research analysts have commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and set a $27.00 price target (down previously from $39.00) on shares of Alder BioPharmaceuticals in a research report on Wednesday, August 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $26.00 price target (down previously from $36.00) on shares of Alder BioPharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research lowered Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. Leerink Swann reaffirmed an “outperform” rating and set a $32.00 price target on shares of Alder BioPharmaceuticals in a research report on Monday, June 12th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $47.00 price target on shares of Alder BioPharmaceuticals in a research report on Wednesday, June 28th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $30.62.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/24/alder-biopharmaceuticals-aldr-given-coverage-optimism-rating-of-0-20.html.

In other Alder BioPharmaceuticals news, Director Stephen M. Dow acquired 25,000 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Tuesday, July 18th. The stock was bought at an average price of $10.00 per share, with a total value of $250,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.60% of the company’s stock.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.